Pfizer and BioNTech pick Covid-19 vaccine and begin pivotal study
Pfizer and BioNTech are starting a large study of a vaccine candidate for Covid-19 aimed at securing approvals — but it’s not the one for which results were released earlier this month.
The companies always said that they planned to pick from among four different candidates, all of which use a technology called messenger RNA to produce a protein on SARS-CoV-2, the virus that causes Covid-19. The vaccine is designed to lead the immune system to recognize the protein, and, it is hoped, to attack the virus.
Read Original Article: Pfizer and BioNTech pick Covid-19 vaccine and begin pivotal study »
